Retrospective / Prospective Clinical Study of AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric Intraocular Lenses
Primary Purpose
Cataract, Presbyopia, Corneal Astigmatism
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL
Sponsored by
About this trial
This is an interventional other trial for Cataract focused on measuring Cataract, Intraocular lens, ACRYSOF IQ ReSTOR + 2.5 D Multifocal Toric IOL
Eligibility Criteria
Inclusion Criteria:
- Must sign an informed consent form and be willing to come in for a visit at least 3 months and not more than 14 months after IOL implantation with the AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL (Models SV25T2, SV25T3, SV25T4 and SV25T5);
- Must be implanted with the correct lens based on preoperative corneal astigmatism as specified in the protocol;
- Must complete a visit within 10 days after IOL implantation;
- Successful capsular bag implantation with no surgical complications;
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- IOL implanted prior to the AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL;
- Ocular or intraocular infection or inflammation at the time of the preoperative visit;
- Any ocular surgery or intraocular laser procedure at or prior to the surgical visit;
- Any conditions affecting the cornea (eg. corneal dystrophy, severe dry eye) at the preoperative visit;
- Retinal conditions (e.g. degenerative retinal conditions, history of retinal detachment, diabetic retinopathy) at the preoperative visit;
- Known history of Type 1 or 2 diabetes for more than 5 years;
- Any ocular or systemic co-morbidity at the preoperative visit;
- Pregnant at the preoperative visit or at the time of Postoperative Visit 2;
- Preoperative corneal astigmatism ≤ 0.50 D;
- Participation in another clinical study at the preoperative visit or at the time of the final study visit;
- Other protocol-specified exclusion criteria may apply.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
ReSTOR Toric +2.5
Arm Description
AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
Outcomes
Primary Outcome Measures
Mean Percent Reduction in Cylinder
Manifest refraction cylinder was measured monocularly (each eye separately) with best correction (phoropter or trial lenses) under photopic (well-lit) lighting conditions using a 100% contrast ETDRS chart at 4 meters (m) from the subject. Percent reduction in cylinder was calculated as the difference between the postoperative magnitude of manifest refractive cylinder and the preoperative magnitude of keratometric cylinder divided by the intended reduction in cylinder [defined as the difference between the intended (from toric calculator) magnitude of the postoperative manifest refractive cylinder and the preoperative keratometric cylinder], multiplied by 100%. One eye (primary eye) contributed to the analysis.
Percentage of Subjects With Manifest Refraction Cylinder ≤ 0.50 D
Manifest refraction cylinder was measured monocularly with best correction under photopic lighting conditions using a 100% contrast ETDRS chart at 4 m from the subject. One eye (primary eye) contributed to the analysis.
Percentage of Subjects (With Preoperative Astigmatism > 1.00 D) With Manifest Refraction Cylinder ≤ 1.00 D
Manifest refraction cylinder was measured monocularly with best correction under photopic lighting conditions using a 100% contrast ETDRS chart at 4 m from the subject. One eye (primary eye) contributed to the analysis.
Mean Uncorrected Distance Visual Acuity
Visual Acuity (VA) was tested monocularly without visual correction under photopic (well-lit) conditions using a 100% contrast ETDRS chart positioned 4 m from the subject. A +0.25 D spherical power additional lens was used to correct for optical infinity. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. One eye (primary eye) contributed to the analysis.
Mean Uncorrected Near Visual Acuity
VA was tested monocularly without visual correction under photopic lighting conditions using a 100% contrast near ETDRS chart set at 40 cm on the nearpoint rod of the phoropter. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. One eye (primary eye) contributed to the analysis.
Mean Uncorrected Intermediate Visual Acuity
VA was tested monocularly without visual correction under photopic lighting conditions using a 100% contrast near ETDRS chart set at 53 cm on the nearpoint rod of the phoropter. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. One eye (primary eye) contributed to the analysis.
Mean Best Corrected Distance Visual Acuity (BCDVA)
VA was tested monocularly with best correction under photopic lighting conditions using a 100% contrast ETDRS chart at 4 m away from the subject. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. One eye (primary eye) contributed to the analysis.
Mean IOL Rotation
Lens axis orientation (position of the lens within the capsular bag) as indicated by indentations on the IOL was assessed during slit lamp examination. IOL rotation (the difference between the achieved lens axis orientation at visit and achieved axis placement at surgery) was measured in degrees. One eye (primary eye) contributed to the analysis.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02176343
Brief Title
Retrospective / Prospective Clinical Study of AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric Intraocular Lenses
Official Title
Retrospective / Prospective Clinical Study of AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric Intraocular Lenses
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
July 21, 2014 (Actual)
Primary Completion Date
August 22, 2014 (Actual)
Study Completion Date
August 22, 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alcon Research
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to characterize the safety and effectiveness of the ACRYSOF IQ ReSTOR +2.5 diopter (D) Multifocal Toric Intraocular Lens (IOL) in subjects at least 3 months and no more than 14 months after IOL implantation.
Detailed Description
This is a retrospective and prospective clinical study comprised of a retrospective chart review for preoperative, surgical and early postoperative data, and a prospective postoperative visit conducted at least 3 months but not more than 14 months after IOL implantation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract, Presbyopia, Corneal Astigmatism
Keywords
Cataract, Intraocular lens, ACRYSOF IQ ReSTOR + 2.5 D Multifocal Toric IOL
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
37 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ReSTOR Toric +2.5
Arm Type
Experimental
Arm Description
AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
Intervention Type
Device
Intervention Name(s)
AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL
Other Intervention Name(s)
Model SV25T2, Model SV25T3, Model SV25T4, Model SV25T5
Intervention Description
Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Primary Outcome Measure Information:
Title
Mean Percent Reduction in Cylinder
Description
Manifest refraction cylinder was measured monocularly (each eye separately) with best correction (phoropter or trial lenses) under photopic (well-lit) lighting conditions using a 100% contrast ETDRS chart at 4 meters (m) from the subject. Percent reduction in cylinder was calculated as the difference between the postoperative magnitude of manifest refractive cylinder and the preoperative magnitude of keratometric cylinder divided by the intended reduction in cylinder [defined as the difference between the intended (from toric calculator) magnitude of the postoperative manifest refractive cylinder and the preoperative keratometric cylinder], multiplied by 100%. One eye (primary eye) contributed to the analysis.
Time Frame
Preoperative and Postoperative Visit (3 to 14 months after IOL implantation)
Title
Percentage of Subjects With Manifest Refraction Cylinder ≤ 0.50 D
Description
Manifest refraction cylinder was measured monocularly with best correction under photopic lighting conditions using a 100% contrast ETDRS chart at 4 m from the subject. One eye (primary eye) contributed to the analysis.
Time Frame
Preoperative and Postoperative Visit (3 to 14 months after IOL implantation)
Title
Percentage of Subjects (With Preoperative Astigmatism > 1.00 D) With Manifest Refraction Cylinder ≤ 1.00 D
Description
Manifest refraction cylinder was measured monocularly with best correction under photopic lighting conditions using a 100% contrast ETDRS chart at 4 m from the subject. One eye (primary eye) contributed to the analysis.
Time Frame
Preoperative and Postoperative Visit (3 to 14 months after IOL implantation)
Title
Mean Uncorrected Distance Visual Acuity
Description
Visual Acuity (VA) was tested monocularly without visual correction under photopic (well-lit) conditions using a 100% contrast ETDRS chart positioned 4 m from the subject. A +0.25 D spherical power additional lens was used to correct for optical infinity. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. One eye (primary eye) contributed to the analysis.
Time Frame
Preoperative and Postoperative Visit (3 to 14 months after IOL implantation)
Title
Mean Uncorrected Near Visual Acuity
Description
VA was tested monocularly without visual correction under photopic lighting conditions using a 100% contrast near ETDRS chart set at 40 cm on the nearpoint rod of the phoropter. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. One eye (primary eye) contributed to the analysis.
Time Frame
Preoperative and Postoperative Visit (3 to 14 months after IOL implantation)
Title
Mean Uncorrected Intermediate Visual Acuity
Description
VA was tested monocularly without visual correction under photopic lighting conditions using a 100% contrast near ETDRS chart set at 53 cm on the nearpoint rod of the phoropter. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. One eye (primary eye) contributed to the analysis.
Time Frame
Preoperative and Postoperative Visit (3 to 14 months after IOL implantation)
Title
Mean Best Corrected Distance Visual Acuity (BCDVA)
Description
VA was tested monocularly with best correction under photopic lighting conditions using a 100% contrast ETDRS chart at 4 m away from the subject. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. One eye (primary eye) contributed to the analysis.
Time Frame
Preoperative and Postoperative Visit (3 to 14 months after IOL implantation)
Title
Mean IOL Rotation
Description
Lens axis orientation (position of the lens within the capsular bag) as indicated by indentations on the IOL was assessed during slit lamp examination. IOL rotation (the difference between the achieved lens axis orientation at visit and achieved axis placement at surgery) was measured in degrees. One eye (primary eye) contributed to the analysis.
Time Frame
Preoperative and Postoperative Visit (3 to 14 months after IOL implantation)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must sign an informed consent form and be willing to come in for a visit at least 3 months and not more than 14 months after IOL implantation with the AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL (Models SV25T2, SV25T3, SV25T4 and SV25T5);
Must be implanted with the correct lens based on preoperative corneal astigmatism as specified in the protocol;
Must complete a visit within 10 days after IOL implantation;
Successful capsular bag implantation with no surgical complications;
Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
IOL implanted prior to the AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL;
Ocular or intraocular infection or inflammation at the time of the preoperative visit;
Any ocular surgery or intraocular laser procedure at or prior to the surgical visit;
Any conditions affecting the cornea (eg. corneal dystrophy, severe dry eye) at the preoperative visit;
Retinal conditions (e.g. degenerative retinal conditions, history of retinal detachment, diabetic retinopathy) at the preoperative visit;
Known history of Type 1 or 2 diabetes for more than 5 years;
Any ocular or systemic co-morbidity at the preoperative visit;
Pregnant at the preoperative visit or at the time of Postoperative Visit 2;
Preoperative corneal astigmatism ≤ 0.50 D;
Participation in another clinical study at the preoperative visit or at the time of the final study visit;
Other protocol-specified exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Manager, GCRA, Surgical
Organizational Affiliation
Alcon Research
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Retrospective / Prospective Clinical Study of AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric Intraocular Lenses
We'll reach out to this number within 24 hrs